SEC Tracker
Get the app

Tyra Biosciences TYRA

Tyra Biosciences reports Q3 2026 financial results

Tyra Biosciences (TYRA) filed an 8-K with the SEC on Nov 10, 2026, 8:03 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash of $700.5 million as of September 30, 2026
  2. 79% overall response rate in Phase 2 IR NMIBC study
  3. Completed $400 million financing
  4. 70 mg QD cohort enrolling for ablative setting

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Tyra Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.